• Citigroup upgrades NASDAQ:KYMR to a "Buy" rating and raises the price target from $80 to $110.
• Kymera's KT-621 shows substantial STAT6 degradation and strong clinical efficacy in Phase 1b trials for atopic dermatitis, advancing to Phase 2b.
• KYMR's stock price surged by 41.55%, reflecting investor optimism on the commercial potential of KT-621 and Kymera's protein-degradation platform.

Kymera Therapeutics, listed on the NASDAQ as KYMR, is a biopharmaceutical company focused on developing novel protein degradation therapies. On December 9, 2025, Citigroup upgraded NASDAQ:KYMR to a "Buy" rating, with the stock priced at $94.3. Citigroup also raised its price target from $80 to $110, indicating confidence in the company's future prospects.

Kymera's recent success in its Phase 1b trials for KT-621 has been a significant factor in this positive outlook. The trials demonstrated substantial STAT6 degradation and strong clinical efficacy in treating atopic dermatitis. These results, which include a favorable safety profile and rapid onset of action, support the advancement of KT-621 to Phase 2b trials for both atopic dermatitis and asthma.

The promising trial outcomes have contributed to a notable increase in KYMR's stock price. The stock has risen by $27.68, a 41.55% increase, reaching a high of $103, its peak in the past year. This surge reflects investor optimism about the commercial potential of KT-621 and Kymera's validated protein-degradation platform.

Kymera's market capitalization is approximately $6.78 billion, highlighting the company's growth and potential in the competitive Type-2 inflammatory disease markets. The successful progression of KT-621 could further enhance Kymera's position in the biopharmaceutical industry, attracting more investor interest and potentially driving the stock price higher.